IOL Chemicals and Pharmaceuticals Ltd
NSE:IOLCP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (14.1), the stock would be worth ₹92.41 (4% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.6 | ₹89.16 |
0%
|
| 3-Year Average | 14.1 | ₹92.41 |
+4%
|
| 5-Year Average | 13.7 | ₹90 |
+1%
|
| Industry Average | 29.2 | ₹191.59 |
+115%
|
| Country Average | 23 | ₹150.81 |
+69%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
IOL Chemicals and Pharmaceuticals Ltd
NSE:IOLCP
|
27.2B INR | 13.6 | 22.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 49.8 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 19.7 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 14.3 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 16.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 13.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.4 | 16.8 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
IOL Chemicals and Pharmaceuticals Ltd
Glance View
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
